Background: For preservation of integrity of appearance and function in a 66-year-old male with an extremely rare case of verrucous carcinoma developing from the subungium of his right thumb, intra-arterial infusion with methotrexate was used.
Objective: To evaluate the effectiveness of arterial infusion with methotrexate in this unusual nail bed cancer.
Methods: Right brachial arterial catheterization and infusion with methotrexate (50 mg) were used every 24 hours together with simultaneous intramuscular injection of 6 mg of leucovorin every 6 hours for 10 days.
Results: At 4 years, 8 months after therapy, the patient was in sustained complete remission with a functionally normal right thumb.
Conclusion: This case study suggests that intra-arterial infusion chemotherapy is a simple and effective method for thumb subungual verrucous carcinoma with the unique advantage of preservation of morphology and functional conditions. It can be considered an effective treatment option.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00042728-200507000-00013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing 100144, China.
Rheumatoid arthritis (RA) and myasthenia gravis (MG) are two distinct autoimmune diseases. Compared with the general population, the incidence of RA is notably higher among patients with MG. Similarly, the rate of MG in patients diagnosed with RA is also significantly increased.
View Article and Find Full Text PDFQuality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings.
Rheumatol Adv Pract
November 2024
Rheumatology, Western Washington Arthritis Clinic, Bothell, WA, USA.
Article Synopsis
- Pegloticase effectively lowers serum urate levels in patients with uncontrolled gout, but its use is limited by the development of anti-drug antibodies.
- Co-administration of methotrexate (MTX) was found to enhance the urate-lowering response and reduce the risk of infusion reactions, benefiting patients with limited treatment options.
- In a study involving 100 patients, those receiving pegloticase and MTX showed greater improvements in gout response rates compared to those receiving pegloticase and a placebo after 52 weeks of treatment.
Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review.
Eye (Lond)
December 2024
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes.
View Article and Find Full Text PDFComparison of methotrexate dosing protocols for graft-versus-host disease prophylaxis after unrelated hematopoietic stem cell transplantation.
Cytotherapy
November 2024
Department of Hematology and Oncology, Kyoto University, Kyoto, Japan.
Background Aims: Methotrexate (MTX) is used as standard graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation. However, the optimal dosing regimen among the various MTX regimens available remains unclear.
Methods: We used the registration data of Kyoto Stem Cell Transplantation Group to compare six MTX dosing protocols in a multicenter retrospective analysis of 816 cases of unrelated bone marrow or peripheral blood stem cell transplantation.
A Spectacular Effect of Tocilizumab in Takayasu Arteritis.
Eur J Case Rep Intern Med
November 2024
Internal Medicine, University Hospital La Rabta, Tunis, Tunisia.
Background: Anti-interleukin-6 receptors (anti-IL-6R) have been a promising new therapeutic alternative in the treatment of Takayasu arteritis.
Case Description: We report the case of a 34-year-old patient with Takayasu arteritis diagnosed in 2017. While she was on corticosteroid and methotrexate, the patient presented twice with clinical and radiological signs of activity, requiring an increase of corticosteroid dose and an increase in the methotrexate dose to 20 mg/week.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!